Radiopharmaceuticals are emerging as a powerful avenue for treating cancer, and Ratio Therapeutics’ CEO and CSO talk specifically how the therapy can combine with immuno-oncology to enhance activity and efficacy, for patient benefit.
Radiopharmaceuticals are emerging as a powerful avenue for treating cancer, and Ratio Therapeutics’ CEO and CSO talk specifically how the therapy can combine with immuno-oncology to enhance activity and efficacy, for patient benefit.